NewsRx Logo Login/Signup
Home Newsletters Products Library About Us Contact -- Search NewsRx

NewsRx | Free Trials
Advertisement
VerticalNews | Global Warming
NewsRx | Free Newsletters
 
----------
------------
NewsRx on Facebook
-----
NewsRx Passes
Press Release Submissions
PR Login
-----
2008 Award Logo
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
-----
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.

Security by Verisign

Search Results for RSR13


Results 1 - 17


 Refine Search
Display Mode: Context | Summary
Findings reported by University of Arizona, U.S., further disease research
2007 SEP 10 ... response of brain metastases to Efaproxiral. "Efaproxiral (Efaproxyn, RSR13), a synthetic allosteric modifier of haemoglobin (Hb), decreases Hb-oxygen (O2 ) binding ...
Subject: University of Arizona, U.S.
Price: $3.00
*
New findings from University of Arizona, U.S., described
2007 JUL 23 ... response of brain metastases to Efaproxiral. "Efaproxiral (Efaproxyn, RSR13), a synthetic allosteric modifier of haemoglobin (Hb), decreases Hb-oxygen (O2 ) binding ...
Subject: University of Arizona, U.S.
Price: $3.00
*
Study findings from University of Arizona, U.S., enhance human health research
2007 JUL 17 ... response of brain metastases to Efaproxiral. "Efaproxiral (Efaproxyn, RSR13), a synthetic allosteric modifier of haemoglobin (Hb), decreases Hb-oxygen (O2 ) binding ...
Subject: University of Arizona, U.S.
Price: $3.00
*
Reports on University of Arizona, U.S., study findings provide new insights
2007 JUN 12 ... response of brain metastases to Efaproxiral. "Efaproxiral (Efaproxyn, RSR13), a synthetic allosteric modifier of haemoglobin (Hb), decreases Hb-oxygen (O2 ) binding ...
Subject: University of Arizona, U.S.
Price: $3.00
*
Recent findings from University of Arizona, U.S., highlighted
2007 MAY 7 ... response of brain metastases to Efaproxiral. "Efaproxiral (Efaproxyn, RSR13), a synthetic allosteric modifier of haemoglobin (Hb), decreases Hb-oxygen (O2 ) binding ...
Subject: University of Arizona, U.S.
Price: $3.00
*
Study data released by University of Arizona, U.S.
2007 FEB 20 ... response of brain metastases to Efaproxiral. "Efaproxiral (Efaproxyn, RSR13), a synthetic allosteric modifier of haemoglobin (Hb), decreases Hb-oxygen (O2 ) binding ...
Subject: University of Arizona, U.S.
Price: $3.00
*
Recent research from University of Rhode Island, U.S., summarized
2007 FEB 5 ... (1966-June 2005) and EMBASE (1980-May 2005) searches using the keywords efaproxiral and RSR13." "Published abstracts over the previous 10 years from various ...
Subject: University of Rhode Island, U.S.
Price: $3.00
*
Researchers from University of Arizona, U.S., report details of new studies and findings
2007 JAN 29 ... response of brain metastases to Efaproxiral. "Efaproxiral (Efaproxyn, RSR13), a synthetic allosteric modifier of haemoglobin (Hb), decreases Hb-oxygen (O2 ) binding ...
Subject: University of Arizona, U.S.
Price: $3.00
*
Medical study results published by University of Rhode Island, U.S.
2007 JAN 22 ... (1966-June 2005) and EMBASE (1980-May 2005) searches using the keywords efaproxiral and RSR13." "Published abstracts over the previous 10 years from various ...
Subject: University of Rhode Island, U.S.
Price: $3.00
*
Researchers' work from University of Arizona, U.S., adds to body of knowledge
2006 DEC 18 ... response of brain metastases to Efaproxiral. "Efaproxiral (Efaproxyn, RSR13), a synthetic allosteric modifier of haemoglobin (Hb), decreases Hb-oxygen (O2 ) binding ...
Subject: University of Arizona, U.S.
Price: $3.00
*
New findings from University of Rhode Island, U.S., detailed
2006 DEC 5 ... (1966-June 2005) and EMBASE (1980-May 2005) searches using the keywords efaproxiral and RSR13." "Published abstracts over the previous 10 years from various ...
Subject: University of Rhode Island, U.S.
Price: $3.00
*
Response of brain metastases to Efaproxiral predicted by red blood cell concentration
2006 AUG 14 ... response of brain metastases to Efaproxiral. "Efaproxiral (Efaproxyn, RSR13), a synthetic allosteric modifier of haemoglobin (Hb), decreases Hb-oxygen (O2 ) binding ...
Subject: Prognostics
Price: $3.00
*
New research from the United States in the area of cancer treatment detailed
2006 JUL 3 ... (NSCLC). According to a study from the United States, "Efaproxiral (RSR13) reduces hemoglobin oxygen-binding affinity, facilitates oxygen release, and increases ...
Subject: Cancer Treatment
Price: $3.00
*
New findings from University of Texas SW Medical Center, Dallas detailed
2006 JUN 21 ... (NSCLC). According to a study from the United States, "Efaproxiral (RSR13) reduces hemoglobin oxygen-binding affinity, facilitates oxygen release, and increases ...
Subject: University of Texas SW Medical Center, Dallas
Price: $3.00
*
Use of efaproxiral in brain metastases from breast cancer improved survival
2006 FEB 6 ... (1966-June 2005) and EMBASE (1980-May 2005) searches using the keywords efaproxiral and RSR13." "Published abstracts over the previous 10 years from various ...
Subject: Breast Cancer
Price: $3.00
*
New findings in the area of Cancer Therapy detailed
2006 JAN 16 ... (NSCLC). According to a study from the United States, "Efaproxiral (RSR13) reduces hemoglobin oxygen-binding affinity, facilitates oxygen release, and increases ...
Subject: Cancer Therapy
Price: $3.00
*
Addition of efaproxiral to S-CRT represents a promising treatment for NSCLC
2005 OCT 24 ... (NSCLC). According to a study from the United States, "Efaproxiral (RSR13) reduces hemoglobin oxygen-binding affinity, facilitates oxygen release, and increases ...
Subject: Cancer Therapy
Price: $3.00
*

Results 1 - 17

-----------------------
Home | Free Newsletters | Products | Article Library | About Us | Contact | Privacy Policy | Search | Visit VerticalNews.com
Copyright © 2009 NewsRx		 PR Login